Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab in pediatric lupus nephritis (real-world study)
ChiCTR2200064053Phase 4Not yet recruiting
- Sponsor
- Children's Hospital of Chongqing Medical University
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of belimumab in lupus nephritis (LN) and systemic lupus erythematosus (SLE) (2 arms), sponsored by Children's Hospital of Chongqing Medical University. Primary endpoints: efficacy and safety. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
belimumab
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on ChiCTR2200064053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200064053.